Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
1.
Arch Soc Esp Oftalmol (Engl Ed) ; 97(2): 77-80, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35152952

ABSTRACT

PURPOSE: The SARS-CoV-2 virus, which causes COVID-19 disease, is transmitted by aerosols or by contact with infected surfaces. The route of entry to the body is through the nasal, oral or conjunctival mucosa. Health workers must use effective protection measures against the entry of the virus into mucous membranes, both physical and antiseptic filters. There is an antiseptic used in Ophthalmology that we believe could have virucidal action against the SARS-CoV-2 virus, formulated based on 0.01% hypochlorous acid. METHODS: An exhaustive search has been carried out in the databases of Pubmed and Web of Science to identify relevant articles on the virucidal activity of hypochlorous acid in different concentrations until October 4, 2020. RESULTS: There is evidence of the virucidal efficacy of 0.01% hypochlorous acid against SARS-CoV-2. According to the different scientific publications reviewed, hypochlorous acid has virucidal efficacy against different viruses, among them, SARS-CoV-2. CONCLUSIONS: The 0.01% hypochlorous acid could act as an effective antiseptic against SARS-CoV-2, exerting a barrier on the mucosa to prevent COVID-19 infection. It can be used on the eyes, nose and mouth. We consider it necessary to assess its use in the protocol for patient health care in ophthalmology consultations, as well as to recommend its use to the general population to reduce viral load and/or prevent transmission of infection. Additional in vivo studies would be required to confirm its antiseptic action.


Subject(s)
Anti-Infective Agents, Local , COVID-19 , Humans , Hypochlorous Acid , SARS-CoV-2
2.
Arch. Soc. Esp. Oftalmol ; 97(2): 77-80, feb.,2022.
Article in Spanish | IBECS | ID: ibc-202739

ABSTRACT

PropósitoEl virus SARS-CoV-2, causante de la enfermedad COVID-19, se transmite por aerosoles o por contacto con superficies infectadas. La ruta de entrada al cuerpo se produce a través de la mucosa nasal, oral o conjuntival. El personal sanitario debe usar medidas de protección efectivas a la entrada del virus en mucosas, tanto filtros físicos como antisépticos. Uno de los antisépticos usados en oftalmología, formulado a base de ácido hipocloroso al 0,01%, consideramos que podría tener acción virucida frente al virus SARS-CoV-2. El objetivo del estudio fue revisar la evidencia científica sobre la actividad virucida del ácido hipocloroso frente al SARS-CoV-2.MétodosSe realizó una búsqueda exhaustiva en las bases de datos de Pubmed y Web of Science para identificar artículos relevantes sobre la actividad virucida del ácido hipocloroso en diferentes concentraciones, publicados hasta el 4 de octubre de 2020.ResultadosLa búsqueda arrojó un total de 20 artículos. Los estudios analizados mostraron pruebas de la eficacia virucida del ácido hipocloroso, a una concentración del 0,01%, frente al SARS-CoV-2, así como frente a otros virus.ConclusionesEl ácido hipocloroso al 0,01% podría actuar como antiséptico eficaz frente al SARS-CoV-2, creando una barrera protectora sobre las mucosas para evitar la entrada del virus y el desarrollo de la infección COVID-19. El producto puede ser aplicado en ojos, nariz y boca, sin efectos nocivos. Por ello, consideramos necesario valorar su uso en el protocolo de atención sanitaria al paciente en consultas de oftalmología, así como recomendar su uso a la población general para disminuir la carga viral y/o evitar transmisión de la infección. No obstante, se requerirían estudios adicionales in vivo para confirmar su acción virucida.


PurposeThe SARS-CoV-2 virus, which causes COVID-19 disease, is transmitted by aerosols or by contact with infected surfaces. The route of entry to the body is through the nasal, oral or conjunctival mucosa. Health workers must use effective protection measures against the entry of the virus into mucous membranes, both physical and antiseptic filters. There is an antiseptic used in Ophthalmology that we believe could have virucidal action against the SARS-CoV-2 virus, formulated based on 0.01% hypochlorous acid.MethodsAn exhaustive search has been carried out in the databases of Pubmed and Web of Science to identify relevant articles on the virucidal activity of hypochlorous acid in different concentrations until October 4, 2020.ResultsThere is evidence of the virucidal efficacy of 0.01% hypochlorous acid against SARS-CoV-2. According to the different scientific publications reviewed, hypochlorous acid has virucidal efficacy against different viruses, among them, SARS-CoV-2.ConclusionsThe 0.01% hypochlorous acid could act as an effective antiseptic against SARS-CoV-2, exerting a barrier on the mucosa to prevent COVID-19 infection. It can be used on the eyes, nose and mouth. We consider it necessary to assess its use in the protocol for patient health care in ophthalmology consultations, as well as to recommend its use to the general population to reduce viral load and / or prevent transmission of infection. Additional in vivo studies would be required to confirm its antiseptic action.


Subject(s)
Humans , Health Sciences , Coronavirus , Review Literature as Topic , Severe acute respiratory syndrome-related coronavirus , Hypochlorous Acid
3.
Arch Soc Esp Oftalmol ; 97(2): 77-80, 2022 Feb.
Article in Spanish | MEDLINE | ID: mdl-34629692

ABSTRACT

PURPOSE: The SARS-CoV-2 virus, which causes COVID-19 disease, is transmitted by aerosols or by contact with infected surfaces. The route of entry to the body is through the nasal, oral or conjunctival mucosa. Health workers must use effective protection measures against the entry of the virus into mucous membranes, both physical and antiseptic filters. There is an antiseptic used in Ophthalmology that we believe could have virucidal action against the SARS-CoV-2 virus, formulated based on 0.01% hypochlorous acid. METHODS: An exhaustive search has been carried out in the databases of Pubmed and Web of Science to identify relevant articles on the virucidal activity of hypochlorous acid in different concentrations until October 4, 2020. RESULTS: There is evidence of the virucidal efficacy of 0.01% hypochlorous acid against SARS-CoV-2. According to the different scientific publications reviewed, hypochlorous acid has virucidal efficacy against different viruses, among them, SARS-CoV-2. CONCLUSIONS: The 0.01% hypochlorous acid could act as an effective antiseptic against SARS-CoV-2, exerting a barrier on the mucosa to prevent COVID-19 infection. It can be used on the eyes, nose and mouth. We consider it necessary to assess its use in the protocol for patient health care in ophthalmology consultations, as well as to recommend its use to the general population to reduce viral load and / or prevent transmission of infection. Additional in vivo studies would be required to confirm its antiseptic action.

4.
Arch. Soc. Esp. Oftalmol ; 96(4): 214-218, abr. 2021. ilus, tab
Article in Spanish | IBECS | ID: ibc-217605

ABSTRACT

La introducción de la angiografía por tomografía de coherencia óptica (OCT-A) ha generado interés en evaluar las alteraciones vasculares en la cabeza del nervio óptico para el diagnóstico y monitorización del glaucoma. El propósito de este estudio es comparar la perfusión del disco óptico entre sujetos normales y sujetos con glaucoma usando OCT-A para detectar cambios en la perfusión del disco óptico. El sistema OCTA AngioVue examinó 40 ojos de 40 pacientes (20 con glaucoma y 20 controles sanos). La densidad de flujo peripapilar radial total (4,5×4,5mm) se midió en diferentes niveles de segmentación. El estudio demostró que el flujo vascular peripapilar de la OCT-A y la exploración de la cabeza del nervio óptico fue mejor en los ojos normales en comparación con los pacientes con glaucoma. Esta revisión proporciona un resumen exhaustivo de las aplicaciones actuales y potenciales más importantes de OCTA en el glaucoma (AU)


The introduction of optical coherence tomography angiography (OCT-A) has generated interest in evaluating vascular dysfunctions in the optic nerve head for the diagnosis and monitoring of glaucoma. The purpose of this study is to compare perfusion of the optic disc between normal subjects and subjects with glaucoma using OCT-A in order to detect changes in perfusion of the optic disc. Using the OCT-A AngioVue® system, an examination was performed on 40 eyes of 40 patients (20 with glaucoma and 20 healthy controls). Total radial peripapillary flow density (4.5×4.5mm) was measured at different levels of segmentation. The study demonstrated that the peripapillary vascular flow of OCT-A and exploration of the optic nerve head was better in the normal eyes compared to glaucoma patients. This review provides a comprehensive summary of the most important current and potential applications of OCT-A in glaucoma (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Glaucoma/diagnostic imaging , Optic Nerve/diagnostic imaging , Computed Tomography Angiography , Tomography, Optical Coherence , Case-Control Studies
5.
Arch Soc Esp Oftalmol (Engl Ed) ; 96(4): 214-218, 2021 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-32675037

ABSTRACT

The introduction of optical coherence tomography angiography (OCT-A) has generated interest in evaluating vascular dysfunctions in the optic nerve head for the diagnosis and monitoring of glaucoma. The purpose of this study is to compare perfusion of the optic disc between normal subjects and subjects with glaucoma using OCT-A in order to detect changes in perfusion of the optic disc. Using the OCT-A AngioVue® system, an examination was performed on 40 eyes of 40 patients (20 with glaucoma and 20 healthy controls). Total radial peripapillary flow density (4.5×4.5mm) was measured at different levels of segmentation. The study demonstrated that the peripapillary vascular flow of OCT-A and exploration of the optic nerve head was better in the normal eyes compared to glaucoma patients. This review provides a comprehensive summary of the most important current and potential applications of OCT-A in glaucoma.

6.
Arch Soc Esp Oftalmol (Engl Ed) ; 95(6): 300-310, 2020 Jun.
Article in English, Spanish | MEDLINE | ID: mdl-32409243

ABSTRACT

OBJECTIVE: Minimize exposure to the SARS-CoV-2, reduce the chances of cross-transmission between patients and healthcare personnel, and prevent the development of postoperative complications from the management of patients with eye diseases during the 2019 coronavirus disease pandemic (COVID-19). METHODS: COVID-19 literature review and consensus establishment between different Spanish ophthalmology societies in order to provide guidelines and recommendations of maximum resources primarily conditioned by the state of alert, confinement and social distancing that occurs in Spain since March 16, 2020. RESULTS: The recommendations will promote the adoption of action and protection measures for eye care in outpatient clinics, surgical areas and hospitalization, for unconfirmed (asymptomatic and symptomatic) and confirmed COVID-19 patients. Measures must be adapted to the circumstances and availability of personal protective equipment in each of the centers and Autonomous Communities, which will be updated according to the pandemic phases and the measures adopted by the Spanish Government. CONCLUSIONS: During the COVID-19 pandemic, attention to the potential health risks to the population caused by coronavirus should prevail over the possible progression of the common eye diseases. Ophthalmologists and other eye care professionals must assume a possible progression of these diseases due to the impossibility of adequate patient follow-up.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Eye Diseases/diagnosis , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Postoperative Complications/prevention & control , Antimalarials/therapeutic use , Asymptomatic Diseases , Blood Safety , COVID-19 , Chloroquine/therapeutic use , Contact Lenses , Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Disease Progression , Eye Diseases/therapy , Humans , Hydroxychloroquine/therapeutic use , Ophthalmologic Surgical Procedures/adverse effects , Ophthalmologic Surgical Procedures/methods , Ophthalmology , Pandemics/prevention & control , Pneumonia, Viral/diagnosis , Pneumonia, Viral/prevention & control , Risk Factors , SARS-CoV-2 , Societies, Medical , Spain , Symptom Assessment/methods , Withholding Treatment
7.
Arch. Soc. Esp. Oftalmol ; 94(8): 391-395, ago. 2019. ilus
Article in Spanish | IBECS | ID: ibc-185625

ABSTRACT

Se trata de un hombre de 45 años con cierre angular y miopía aguda bilateral tras inicio de tratamiento con topiramato por dependencia al alcohol y la heroína. La tomografía de coherencia óptica Visante(R) y la ecografía ocular muestran efusión ciliocoroidea bilateral como mecanismo fisiopatológico. El tratamiento consistió en la retirada del topiramato, y la utilización de hipotensores oculares, ciclopléjico y corticoides tópicos, con lo cual se resolvió el síndrome de efusión ciliocoroidea. La tomografía de coherencia óptica Visante(R) y la ecografía ocular son herramientas útiles en el diagnóstico y seguimiento de los pacientes con cierre angular y miopía en el contexto del síndrome de efusión ciliocoroidea secundario a topiramato. Debido al amplio espectro de indicaciones de esta medicación, tanto el personal sanitario que lo indica como los oftalmólogos, deben conocer las posibles manifestaciones oculares atribuidas a este medicamento


A 45 year-old man with bilateral acute angle-closure and myopia after starting treatment with topiramate, secondary to alcohol and heroin dependence. Using Visante(R) OCT (Optical Coherence Tomography) and B-scan Ultrasound he was diagnosed with bilateral ciliochoroidal effusion as the pathophysiological mechanism. Topiramate was stopped and ocular hypotensive therapy with a topical cycloplegic and corticosteroids were started, resolving ciliochoroidal effusion syndrome. Visante(R) OCT and B-scan Ultrasound are useful tools for the diagnosis and follow-up of patients with acute angle-closure and myopia due to topiramate. As a result of broad spectrum of indications for topiramate, physicians and ophthalmologists should be aware of the possible ophthalmological manifestations attributable to this drug


Subject(s)
Humans , Male , Middle Aged , Anticonvulsants/adverse effects , Microscopy, Acoustic/methods , Tomography, Optical Coherence/methods , Topiramate/adverse effects , Adrenal Cortex Hormones/therapeutic use , Alcoholism , Follow-Up Studies , Glaucoma, Angle-Closure/chemically induced , Glaucoma, Angle-Closure/diagnostic imaging , Glaucoma, Angle-Closure/drug therapy , Heroin Dependence , Mydriatics/therapeutic use , Myopia/chemically induced , Myopia/drug therapy
8.
Arch Soc Esp Oftalmol (Engl Ed) ; 94(8): 391-395, 2019 Aug.
Article in English, Spanish | MEDLINE | ID: mdl-30738599

ABSTRACT

A 45 year-old man with bilateral acute angle-closure and myopia after starting treatment with topiramate, secondary to alcohol and heroin dependence. Using Visante® OCT (Optical Coherence Tomography) and B-scan Ultrasound he was diagnosed with bilateral ciliochoroidal effusion as the pathophysiological mechanism. Topiramate was stopped and ocular hypotensive therapy with a topical cycloplegic and corticosteroids were started, resolving ciliochoroidal effusion syndrome. Visante® OCT and B-scan Ultrasound are useful tools for the diagnosis and follow-up of patients with acute angle-closure and myopia due to topiramate. As a result of broad spectrum of indications for topiramate, physicians and ophthalmologists should be aware of the possible ophthalmological manifestations attributable to this drug.


Subject(s)
Anticonvulsants/adverse effects , Choroidal Effusions/diagnostic imaging , Microscopy, Acoustic/methods , Tomography, Optical Coherence/methods , Topiramate/adverse effects , Adrenal Cortex Hormones/therapeutic use , Alcoholism , Choroidal Effusions/complications , Choroidal Effusions/drug therapy , Follow-Up Studies , Glaucoma, Angle-Closure/chemically induced , Glaucoma, Angle-Closure/diagnostic imaging , Glaucoma, Angle-Closure/drug therapy , Heroin Dependence , Humans , Male , Middle Aged , Mydriatics/therapeutic use , Myopia/chemically induced , Myopia/drug therapy
9.
Arch. Soc. Esp. Oftalmol ; 93(5): 239-241, mayo 2018. ilus
Article in Spanish | IBECS | ID: ibc-173129

ABSTRACT

CASO CLÍNICO: Mujer de 53 años con agujero macular estadio 2, que recibió como primera opción terapéutica una inyección de ocriplasmina, pero a la que se le tuvo que practicar vitrectomía pars plana por aumento del agujero macular postinyección. La ganancia visual tras la cirugía fue mínima a pesar del cierre del agujero, lo que podría explicarse por la atrofia retiniana externa como consecuencia de los potenciales mecanismos tóxicos asociados a ocriplasmina. Discusión: Son necesarios más estudios para entender el completo impacto de la ocriplasmina en la función visual a largo plazo


CASE REPORT: A 53 year-old woman with a stage 2 macular hole received ocriplasmin injection as a first approach. She subsequently underwent pars plana vitrectomy due to enlargement of the hole post-injection. The visual gain following the surgery was minimal despite closure of the hole. This could be explained by outer retina atrophy as a consequence of potential toxic mechanisms related to ocriplasmin. DISCUSSION: Further studies may be warranted to fully understand the impact of ocriplasmin on long-term visual function


Subject(s)
Humans , Female , Middle Aged , Retinal Diseases/complications , Retinal Perforations/chemically induced , Retinal Perforations/surgery , Vitreous Detachment/drug therapy , Vitrectomy/methods , Fibrinolysin/administration & dosage , Intravitreal Injections , Treatment Failure , Retinal Diseases/chemically induced , Minimally Invasive Surgical Procedures/methods , Visual Acuity , Fibrinolysin/adverse effects
10.
Arch Soc Esp Oftalmol (Engl Ed) ; 93(5): 239-241, 2018 May.
Article in English, Spanish | MEDLINE | ID: mdl-29402498

ABSTRACT

CASE REPORT: A 53 year-old woman with a stage 2 macular hole received ocriplasmin injection as a first approach. She subsequently underwent pars plana vitrectomy due to enlargement of the hole post-injection. The visual gain following the surgery was minimal despite closure of the hole. This could be explained by outer retina atrophy as a consequence of potential toxic mechanisms related to ocriplasmin. DISCUSSION: Further studies may be warranted to fully understand the impact of ocriplasmin on long-term visual function.


Subject(s)
Fibrinolysin/adverse effects , Peptide Fragments/adverse effects , Retinal Diseases/chemically induced , Female , Fibrinolysin/therapeutic use , Humans , Middle Aged , Peptide Fragments/therapeutic use , Retinal Perforations/drug therapy , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...